Under construction – not a live service
Sign in
Taking peoplePhase 3

Compares mezigdomide with pomalidomide in relapsed or refractory multiple myeloma

Tests mezigdomide, bortezomib and dexamethasone against pomalidomide combination in adults with myeloma.

Key facts

Who runs it
Celgene
Where
Bucharest, Cluj-Napoca, and Iași, RomaniaSee the 3 sitesAlso in 28 other countries, 263 sites
Registry title
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Status
Recruiting
Phase
Phase 3
People taking part
810 people, planned
Started
20 Sept 2022
Expected to end
30 Nov 2033
Type of study
Interventional, 2 groups
Treatments tested
  • mezigdomide
  • Pomalidomide
  • Bortezomib
  • Dexamethasone
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with multiple myeloma that came back or stopped responding to treatment. They must have had 1 to 3 earlier treatments, including lenalidomide.

Age
18 years or older
Sex
Men and women can join
Disease stage
Relapsed or refractory multiple myeloma with measurable disease (M-protein ≥ 0.5 g/dL in blood, or ≥ 200 mg per 24-hour urine, or serum free light chain > 100 mg/L with an abnormal kappa/lambda ratio)
Earlier treatment
Must have had 1 to 3 earlier lines of myeloma treatment, with at least a minimal response to one of them. Must have had prior lenalidomide. Must not have had mezigdomide or pomalidomide.

Main reasons for not taking part

  • Disease got worse during, or within 60 days of, a proteasome inhibitor (some exceptions apply)
  • Earlier bortezomib treatment did not bring at least a minimal response, or was stopped because of side effects
  • Earlier treatment with mezigdomide or pomalidomide
  • Other criteria set by the study protocol

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Participant has documented diagnosis of MM and measurable disease, defined as any of the following:
  • M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or
  • M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP)
  • For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio
  • Participants received 1 to 3 prior lines of antimyeloma therapy
  • Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy

Who cannot take part

  • Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:
  • Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded
  • Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded
  • For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity
  • Participant has had prior treatment with mezigdomide or pomalidomide
  • Other protocol-defined Inclusion/Exclusion criteria apply

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Which of these best describes your myeloma treatment so far?
  • Have you ever taken lenalidomide (also called Revlimid), a tablet medicine for myeloma?
  • Has a doctor told you that your myeloma can be measured in your blood or urine tests?

Where in Romania

Also in 28 other countries, 263 sites

  • BucharestHospital not named in the registryNo longer taking part
  • Cluj-NapocaHospital not named in the registryNo longer taking part
  • IașiHospital not named in the registryNo longer taking part

About the trial

What the trial wants to find out

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

The 2 groups in the trial

  • MeziVd (mezigdomide, bortezomib and dexamethasone)Treatment being tested

    Treatment: mezigdomide, Bortezomib, and Dexamethasone

  • PVd (pomalidomide, bortezomib and dexamethasone)Treatment being tested

    Treatment: Pomalidomide, Bortezomib, and Dexamethasone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Plain-language title
Compares mezigdomide with pomalidomide in relapsed or refractory multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05519085, who can take part
Record updated
30 October 2026